<DOC>
	<DOCNO>NCT00002155</DOCNO>
	<brief_summary>To compare effect CD4 count serum viral RNA among HIV-seropositive , zidovudine ( AZT ) -experienced patient three treatment arm : indinavir sulfate ( MK-639 ; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC .</brief_summary>
	<brief_title>A Six-Month Safety Antiviral Study HIV-1 Seropositive , AZT-Experienced Patients With CD4 Counts Less Than Equal 50 Cells/mm3 Evaluate MK-639 Alone Versus Zidovudine ( AZT ) 3TC Versus Combination MK-639 With AZT/3TC</brief_title>
	<detailed_description>AZT-experienced patient randomize receive MK-639/AZT/3TC MK-639 alone AZT/3TC . Additionally , patient receive &lt; 6 month AZT intolerant receive prior 3TC require concomitant rifampin therapy may receive open-label MK-639 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed patient : Standard prophylaxis opportunistic infection . Continuation treatment opportunistic infection . Allowed openlabel study patient : Rifampin . Patients must : HIV positivity . CD4 count &lt; = 50 cells/mm3 . More 6 month prior AZT ( blind study ) . NOTE : Patients openlabel study must AZT intolerance &lt; 6 month prior AZT . Prior Medication : Required blind study patient : &gt; 6 month prior AZT . Required openlabel study patient : &lt; 6 month prior AZT . Allowed openlabel study patient : Prior 3TC . Exclusion Criteria Concurrent Medication : Excluded patient : Immunosuppressants . Excluded blind study patient : AZT , ddI , ddC , d4T . Rifampin . Excluded openlabel study patient : 3TC . Prior Medication : Excluded patient : Prior protease inhibitor . Investigational agent immunomodulators within 30 day prior study entry . Immunosuppressants within 2 week prior study entry . Excluded blind study patient : Any prior 3TC . AZT , ddI , ddC , d4T within 2 week prior study entry . Excluded openlabel study patient : 3TC within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1996</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
</DOC>